Publications

English only

Science is our DNA and the foundation of BioNTech’s approach

We maintain a culture of scientific excellence and will continue to drive future innovation through sharing our key findings in a peer reviewed format

mRNA Therapeutics

Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, Omokoko T, Vormehr M, Albrecht C, Paruzynski A, Kuhn AN, Buck J, Heesch S, Schreeb KH, Müller F, Ortseifer I, Vogler I, Godehardt E, Attig S, Rae R, Breitkreuz A, Tolliver C, Suchan M, Martic G, Hohberger A, Sorn P, Diekmann J, Ciesla J, Waksmann O, Brück AK, Witt M, Zillgen M, Rothermel A, Kasemann B, Langer D, Bolte S, Diken M, Kreiter S, Nemecek R, Gebhardt C, Grabbe S, Höller C, Utikal J, Huber C, Loquai C, Türeci Ö. (2017).
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.
Nature. Jul 13; 547(7662):222-226.
Stadler CR, Bähr-Mahmud H, Celik L, Hebich B, Roth AS, Roth RP, Karikó K, Türeci Ö, Sahin U. (2017).
Elimination of large tumors in mice by mRNA-encoded bispecific antibodies.
Nature Medicine Jul; 23(7):815-817. doi: 10.1038/nm.4356. Epub 2017 Jun 12.
Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, Dowd KA, Sutherland LL, Scearce RM, Parks R, Wagner W, Granados A, Greenhouse J, Walker M, Willis E, Yu JS, McGee CE, Sempowski GD, Mui BL, Tam YK, Huang YJ, Vanlandingham D, Holmes VM, Balachandran H, Sahu S, Lifton M, Higgs S, Hensley SE, Madden TD, Hope MJ, Karikó K, Santra S, Graham BS, Lewis MG, Pierson TC, Haynes BF, Weissman D. (2017).
Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination.
Nature. Mar 9; 543(7644):248-251.
Grabbe S, Haas H, Diken M, Kranz LM, Langguth P, Sahin U. (2016).
Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma.
Nanomedicine (Lond). Oct; 11(20):2723-2734.
Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, Meng M, Fritz D, Vascotto F, Hefesha H, Grunwitz C, Vormehr M, Hüsemann Y, Selmi A, Kuhn AN, Buck J, Derhovanessian E, Rae R, Attig S, Diekmann J, Jabulowsky RA, Heesch S, Hassel J, Langguth P, Grabbe S, Huber C, Türeci Ö, Sahin U. (2016).
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.
Nature. Jun 1; 534(7607):396-401.
Poleganov MA, Eminli S, Beissert T, Herz S, Moon JI, Goldmann J, Beyer A, Heck R, Burkhart I, Barea Roldan D, et al (2015).
Efficient Reprogramming of Human Fibroblasts and Blood-Derived Endothelial Progenitor Cells Using Nonmodified RNA for Reprogramming and Immune Evasion.
Hum Gene Ther. Nov; 26(11):751-766.
Kowalska J, Wypijewska del Nogal A, Darzynkiewicz ZM, Buck J, Nicola C, Kuhn AN, Lukaszewicz M, Zuberek J, Strenkowska M, Ziemniak M, et al (2014).
Synthesis, properties, and biological activity of boranophosphate analogs of the mRNA cap: versatile tools for manipulation of therapeutically relevant cap-dependent processes.
Nucleic Acids Res. 42(16):10245-10264.
Sahin U, Kariko K and Tureci O (2014).
mRNA-based therapeutics–developing a new class of drugs.
Nat Rev Drug Discov. Oct; 13(10):759-780.
Kreiter S, Vormehr M, van de Roemer N, Diken M, Lower M, Diekmann J, Boegel S, Schrors B, Vascotto F, Castle JC et al (2015).
Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
Nature. Apr 30; 520(7549):692-696.
Castle JC, Loewer M, Boegel S, de Graaf J, Bender C, Tadmor AD, Boisguerin V, Bukur T, Sorn P, Paret C et al. (2014).
Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma.
BMC Genomics. 15:190.
Castle JC, Kreiter S, Diekmann J, Lower M, van de Roemer N, de Graaf J, Selmi A, Diken M, Boegel S, Paret C et al (2012).
Exploiting the mutanome for tumor vaccination.
Cancer Res. Mar 1; 72(5):1081-1091.
Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, Tureci O and Sahin U (2010).
Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity.
Cancer Res. Nov 15; 70(22):9031-9040.

Engineered Cell Therapies

Simon P, Omokoko TA, Breitkreuz A, Hebich L, Kreiter S, Attig S, Konur A, Britten CM, Paret C, Dhaene K et al (2014).
Functional TCR retrieval from single antigen-specific human T cells reveals multiple novel epitopes.
Cancer Immunol Res. Dec; 2(12):1230-1244.
Omokoko T, Simon P, Tureci O and Sahin U (2015).
Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies.
Oncoimmunology. Jul; 4(7):e1005523.

Antibodies

Microbodies

Sommerhoff CP, Avrutina O, Schmoldt HU, Gabrijelcic-Geiger D, Diederichsen U, Kolmar H (2010).
Engineered cystine knot miniproteins as potent inhibitors of human mast cell tryptase beta.
J Mol Biol. 2010 Jan 8;395(1):167-75. doi: 10.1016/j.jmb.2009.10.028. Epub 2009 Oct 21. PMID: 19852971.
Avrutina O, Schmoldt HU, Gabrijelcic-Geiger D, Wentzel A, Frauendorf H, Sommerhoff CP, Diederichsen U, Kolmar H. (2008).
Head-to-tail cyclized cystine-knot peptides by a combined recombinant and chemical route of synthesis.
Chembiochem. 2008 Jan 4;9(1):33-7. PMID: 18058774.
Krause S, Schmoldt HU, Wentzel A, Ballmaier M, Friedrich K, Kolmar H. (2007).
Grafting of thrombopoietin-mimetic peptides into cystine knot miniproteins yields high-affinity thrombopoietin antagonists and agonists.
FEBS J. 2007 Jan;274(1):86-95. Epub 2006 Nov 27. PMID: 17147697.

Bispecific Antibodies

Stadler CR, Bähr-Mahmud H, Celik L, Hebich B, Roth AS, Roth RP, Karikó K, Türeci Ö, Sahin U. (2017).
Elimination of large tumors in mice by mRNA-encoded bispecific antibodies.
Nature Medicine Jul; 23(7):815-817. doi: 10.1038/nm.4356. Epub 2017 Jun 12.
Christiane R Stadler, Hayat Bähr-Mahmud, Laura M Plum, Kathrin Schmoldt, Anne C Kölsch, Özlem Türeci & Ugur Sahin (2015).
Characterization of the First-in-Class T-Cell Engaging Bispecific Single-Chain Antibody for Targeted Immunotherapy of Solid Tumors Expressing the Oncofetal Protein Claudin 6.
OncoImmunology, 5:3, e1091555, DOI: 10.1080/2162402X.2015.1091555.